News & Events

StageBio Welcomes Lori Ball as Chief Executive Officer

StageBio Announces Lori Ball has been appointed as new CEO for StageBio, who brings a history of global leadership in the life sciences industry. Ms Ball will succeed Tom Galati, former CEO and Founder of StageBio, who will remain an integral part of the board of directors. Ms Ball will begin her role January 18, 2022.

Mount Jackson, VA – January 18, 2022 – StageBio, a leading international provider of GLP-compliant research, preclinical and clinical histopathology and biospecimen archiving services for life sciences industry, today announced that it has appointed Lori Ball as its Chief Executive Officer (CEO). In her new position, Ms. Ball will be responsible for providing leadership and strategic direction for StageBio, including growth planning, operations, organizational development, risk management, and quality.

“Lori has the requisite global business expansion, therapeutic development, and regulatory expertise to help us take StageBio through the next phase of strategic growth. Lori shares our vision for making StageBio the partner of choice for therapeutic and medical device developers requiring histology, pathology, and archiving globally. I am delighted to welcome Lori to the StageBio executive team.” - StageBio Founder and Board Member, Tom Galati.

“I am thrilled to be joining StageBio at this point in its growth trajectory. StageBio has an impressive customer base and has assembled a robust portfolio of services as well as a talented team with the experience, scientific rigor, and commitment to high quality service that life science customers demand. Together, we have the potential to dramatically enhance life science research.” - Lori Ball, CEO.

Before joining StageBio, Ms. Ball was the COO at BioIVT, a world-leader in providing biological products and services to life science and pharmaceutical companies. At BioIVT Lori was tasked with expanding and operationalizing all business units and functions across 20+ locations around the world.

Ms. Ball also held additional significant leadership roles at market leading research companies such as BioStorage Technologies, Inc. (acq. Brooks Life Science) and Covance, Inc. (acq. Labcorp).

Ms. Ball has in-depth knowledge and experience of the global research environment and was co-founder of The Global Initiative for the Ethical use of Human Specimens (the “GIFT Initiative”).

A strong mentor and a passionate advocate for her mentees, Ms. Ball has served as the National Board Chair for Pass the Torch for Women Foundation and is a member of the CICF Women’s Fund Board of Advisors. She also serves on the Anderson University Falls School of Business Marketing Advisory Board and Athletics Alumni Engagement Council.

About StageBio

StageBio is a leading international provider of GLP-compliant research, preclinical and clinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device, and contract research industries.

Formed through the merger of Histo-Scientific Research Laboratories (HSRL), Vet Path Services, Inc. (VPS), Tox Path Specialists (TPS), Alizée Pathology, and TPL Path Labs, StageBio represents the combined capabilities of the most well-respected sources of high-quality histology, pathology, and archiving services in the preclinical and clinical research and development market globally.

StageBio's integrated offering includes specialty histology, tissue analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to regulatory approval, detailed pathology reporting for GLP studies, medical device pathology, neuro pathology, investigational pathology, immunohistochemistry (IHC), multiplex immunohistochemistry, in situ hybridization (ISH), imaging, and image analysis. These services allow us to support researchers with the broadest range of solutions at every stage—from discovery through clinical development.

The company operates six state-of-the-art sites in the U.S. and one facility in Germany, serving customers across the Americas, Europe, Australia, and Asia. We continue to make substantial investments in our facility and technology infrastructure to meet the growing demand for high-quality histopathology and biospecimen archiving services.

At StageBio we have a team of over 25 board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity and client satisfaction.

Back to Index

Upcoming Events

ASGCT (American Society of Gene and Cell Therapy)

May 16-19, 2022, Walter E. Washington Convention Center, Washington, D.C.

Society of French Pathology Toxicology

May 19-20, Toulouse, France
Listen to our presentation by Dr. Serge Rousselle, CSO, on the scientific value of histopathological evaluation during the nonclinical safety assessment of medical devices

Popular Posts

Learn more about StageBio’s COVID-19 response